期刊文献+

电子止吐仪联合盐酸帕洛诺司琼预防高致吐化疗药物所致急性胃肠道反应的研究 被引量:7

暂未订购
导出
摘要 目的观察电子止吐仪联合盐酸帕洛诺司琼预防高致吐化疗药物所致急性胃肠道反应的疗效。方法将120例接受高致吐化疗药物治疗的患者随机分为2组:试验组60例应用电子止吐仪联合盐酸帕洛诺司琼,对照组60例应用帕洛诺司琼。观察和记录2组自化疗开始到化疗结束24 h内恶心、呕吐的发生情况。结果试验组和对照组呕吐反应完全控制率分别为40%,35%,2组大致相当(P>0.05);有效率分别为95%,78%,2组比较差异有统计学意义(P<0.05)。试验组和对照组恶心反应在完全控制率分别为37%,30%,2组大致相当(P>0.05);有效率分别为90%,77%,2组比较差异有统计学意义(P<0.05)。结论电子止吐仪联合盐酸帕洛诺司琼预防高致吐化疗药物所致急性胃肠道反应优于单用盐酸帕洛诺司琼,可作为防治高致吐化疗药物所致急性期呕吐的常规措施。
出处 《现代中西医结合杂志》 CAS 2015年第27期3001-3003,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献13

  • 1Richard JG. New agents, new treatment and antiemetic therapy [ J ]. Semin Oncol,2002,29( 1 ) :Sl19 - S124.
  • 2Rabasseda X. Ramosetron, a 5 - HT3 receptor antagonist for the control of nausea and vomiting [ J ]. Drugs Today (Barc) , 2002,38 (2) :75 -89.
  • 3Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting:Current and new standards in the antiemetie prophylaxis and treatment[ J]. Eur J Cancer,2005,41 (2) :199.
  • 4Dranitsaris G, Lcung P, Ciotti R, et al. A multinational study to measure the value that patients with cancer place on improved eme- sis control following cisplatin chemotherapy[ J]. Pharmacoeconom- ics,2001,19(9) :955 -967.
  • 5Ingersoll GL, Wasilewski A, Hailer M, et al. Effect of concord grape juice on chemotherapy-induced nausea and vomiting results of a pi- lot study[J]. Oncol Nurs Forum,2010,37(2) :213 -221.
  • 6Ingersoll GL,Wasilewski A, Hailer M,et al. Effect of concord grape juice on chemotherapy-induced nausea and vomiting results of a pi- lot study[J]. Oncol Nurs Forum,2010,37(2):213-221.
  • 7吴德芹,陈安九,张宏文,葛萍,王永庆,欧宁,孟玲.高效液相色谱-大气压化学电离源-质谱法测定人血浆中帕洛诺司琼浓度[J].南京医科大学学报(自然科学版),2011,31(6):903-906. 被引量:2
  • 8李瑞超,郑丽君,邱红.盐酸帕洛诺司琼与托烷司琼预防含大剂量顺铂方案化疗所致呕吐的疗效[J].中华肿瘤杂志,2012,34(3):228-231. 被引量:41
  • 9陈映霞,秦叔逵,程颖,陈振东,李进,张清媛,潘良熹.盐酸帕洛诺司琼预防化疗性恶心呕吐的多中心双盲随机对照临床研究[J].临床肿瘤学杂志,2007,12(3):161-165. 被引量:48
  • 10Navafi RM, Reinhardt RR, Gralla R J, et al. Reduction of cisplatin - induced emesis by a selective ncurokinin - 1 - receptor antagonist [J]. N EnglJMed,1999,340(3):190-195.

二级参考文献30

  • 1王海凤,王东凯.5-HT_3受体阻滞剂帕洛诺司琼[J].中国新药杂志,2006,15(10):833-835. 被引量:16
  • 2陈映霞,秦叔逵,程颖,陈振东,李进,张清媛,潘良熹.盐酸帕洛诺司琼预防化疗性恶心呕吐的多中心双盲随机对照临床研究[J].临床肿瘤学杂志,2007,12(3):161-165. 被引量:48
  • 3陈艳,丁莉坤,孟玲燕,丁黎,杨林,文爱东.盐酸帕洛诺司琼注射液人体药动学研究[J].中国新药杂志,2007,16(10):806-809. 被引量:14
  • 4Aapro M, Blower P. 5-hydroxytryptamine Type-3 receptor antagonists for chemotherapy-induced and radiotherapyinduced nausea and emesis:can we safely reduce the dose of administered agents? [J]. Cancer,2005,104(1) : 1-18.
  • 5Eisenberg P, MacKintosh FR,Ritch P,et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic eisplatin-based chemotherapy: a dose-ranging clinical study [J]. Ann Oncol, 2004,15 (2) : 330-337.
  • 6Stohz R,Parisi S,Shah A,et al. Pharmacokinetics, metabolism and excretion of intravenous [14C]palonosetron in healthy human volunteers [J]. Biopharm Drug Dispos, 2004,25 (8) : 329-337.
  • 7Ding L, Chen Y, Yang L, et al. Determination of palonosetron in human plasma by liquid chromatography-electrospray ionization-mass spectrometry [J]. J Phann Biomed Anal, 2007, 44(2) :575-580.
  • 8Hunt TL, Gallagher SC, Cullen MT Jr,et al. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects [J]. J Clin Pharmacol, 2005,45 (5) : 589-596.
  • 9彭学清,曾玲,周述香,刘义钊,张勇.我国健康受试者体内帕洛诺司琼的药物动力学研究[J].中南药学,2007,5(4):322-325. 被引量:4
  • 10Geling O, Eichler HG. Should 5-hydmxytrypanfine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oneol, 2005, 23 : 1289-1294.

共引文献87

同被引文献80

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部